For how we live.
Three 2025 reviews of the same drugs reach three answers: a matched cohort finds less cardiovascular disease on biologics, a network meta-analysis flags one drug as raising events, and 43 trials find nothing.
In the two pivotal dupilumab trials, 36% to 38% reached that endpoint at 16 weeks against 8% to 10% on placebo. A 97-trial network review finds the newer drugs clustered closely together.
The FDA's approval bar requires no clinically meaningful difference from the original, and a large switching trial found no loss of control. The savings gap is a market problem, not a safety one.
A registry snapshot of 13,455 adults measures how far the biologic era has moved severe asthma toward remission, and finds the inflammation these drugs target still detectable in most patients.
Narsoplimab clears the FDA on a single-arm study of 28 adults plus 19 patients from an expanded access programme. Sixty-one per cent responded. Seven per cent had a fatal adverse reaction.